CaliPharms(OTC) KGET

Market Cap$11.90K

Since IPO (2013)-100%

5 Year+0%

1 Year+0%

1 Month+0%

$0.00

+0.00%

+0.00Today

CaliPharms last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-08-07

CaliPharms stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-07-29
1 month	+0%	USD 0.00	2026-07-07
3 month	+0%	USD 0.00	2026-05-07
Year to date	+0%	USD 0.00	2025-12-31
1 year	+0%	USD 0.00	2025-08-07
3 year	+0%	USD 0.00	2023-08-02
5 year	+0%	USD 0.00	2021-08-06
Since inception	-99.98%	USD 0.00	2013-12-24

CaliPharms Financials at a Glance

Market Cap

$11.90K

Revenue (TTM)

$112.47K

Net Income (TTM)

-$6.39M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-25.65 (Low)

Dividend

$0.00

Beta (Volatility)

-25.65 (Low)

Price

$0.00

Volume

141,571

Open

$0.00

Price

$0.00

Volume

141,571

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

N/A

Dividend

$0.00

Beta (Volatility)

-25.65 (Low)

Price

$0.00

Volume

141,571

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

N/A

KGET News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CaliPharms

CaliPharms, Inc. is a company focused on the medicinal cannabis industry, particularly in the THC and CBD-infused beverage sector. Established in 2017, the company operates from Temecula, California, and aims to capitalize on the growing demand for cannabis-based products across the United States.

Products and Services

THC and CBD-infused beverages
Innovative product development in the cannabis sector
Focus on quality and compliance in manufacturing

Growth Outlook

Expanding market for cannabis beverages projected to grow significantly
Increased consumer acceptance of cannabis products driving demand
Strategic partnerships may enhance distribution capabilities

Financial Highlights

Recent quarterly revenue of 59,959, showing potential for growth
Trailing twelve months (TTM) revenue of 132,465 indicates upward trend
Operating expenses reflect investment in future growth despite current losses

CaliPharms, Inc. operates in a rapidly evolving industry with significant growth potential. The company's focus on THC and CBD-infused beverages positions it well to take advantage of the increasing consumer interest in cannabis products. Recent financial data indicates a revenue increase, suggesting that the company is on a path toward improved performance. The strategic outlook highlights opportunities for expansion and partnerships, which could further enhance market presence. Investors may find the company's commitment to quality and compliance appealing as it navigates the complexities of the cannabis market.

AI Generated • Jul 18, 2026

Industry

Machinery

Sector

Industrials

Headquarters

Temecula, CA 92592, US

KGET Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-11222.67%

Net Income Margin

-11861.40%

Return on Equity

19.88%

Return on Capital

N/A

Return on Assets

-7495.36%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.90K

Shares Outstanding

11.86B

Volume

141.57K

Avg. Volume

458.27K

Financials (TTM)

Gross Profit

-$30.57K

Operating Income

-$822.17K

EBITDA

-$1.09M

Operating Cash Flow

-$703.06K

Capital Expenditure

$0.00

Free Cash Flow

-$703.06K

Cash & ST Invst.

$17.16K

Total Debt

$222.55K

CaliPharms Performance Analysis

CaliPharms sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2013-12-31	N/A
Q1	2014-03-31	N/A
Q2	2014-06-30	68.6%
Q3	2014-09-30	81.9%

CaliPharms sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2013-12-31	100.0%
Q1	2014-03-31	N/A
Q2	2014-06-30	100.0%
Q3	2014-09-30	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q3 2014YOY CHG

Revenue

$59.96K

N/A

Gross Profit

-$7.44K

N/A

Gross Margin

-12.41%

N/A

Market Cap

$11.90K

N/A

Market Cap/Employee

$2.98K

N/A

Employees

N/A

Net Income

-$4.18M

-11286.6%

EBITDA

-$231.56K

-25.5%

Quarterly Fundamentals

Name

Q3 2014YOY CHG

Total Cash

$17.16K

+59079.3%

Total Debt

$222.55K

+8682.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$222.55K

+8682.7%

Return on Assets

-74.95%

N/A

Return on Invested Capital

34.01%

N/A

Free Cash Flow

-$249.88K

-12332.0%

Operating Cash Flow

-$249.88K

-12332.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

MTMWMatmown, Inc.

MTMWMatmown, Inc.$0.00N/A

TFZIThe Fight Zone, Inc.

TFZIThe Fight Zone, Inc.$0.00+0.00%

CPYCFCompliance Energy Corporation

CPYCFCompliance Energy Corporation$0.00+0.00%

GTCPGeorgetown Corporation

GTCPGeorgetown Corporation$0.00+0.00%

RNWBThe Renewable Corporation

RNWBThe Renewable Corporation$0.00-99.97%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$138.74+0.04%

ACHRArcher Aviation

ACHRArcher Aviation$6.26+0.12%

NVDANvidia

NVDANvidia$217.55-0.03%

INTCIntel

INTCIntel$97.52-0.04%

ONDSOndas

ONDSOndas$9.31+0.02%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$8.21+0.01%

RIGTransocean

RIGTransocean$5.72+0.09%

Questions About KGET

What is the current price of CaliPharms?

CaliPharms is trading at $0.00 per share.

What is the 52-week range for CaliPharms?

Over the past 52 weeks, CaliPharms has traded between $0.00 and $0.01.

How much debt does CaliPharms have?

CaliPharms total debt is unavailable.

How much cash does CaliPharms have on hand?

CaliPharms does not have cash on hand data available.

What is CaliPharms’s dividend yield?

CaliPharms does not currently have a dividend yield.

CaliPharms(OTC) KGET

CaliPharms Financials at a Glance

KGET News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About CaliPharms

KGET Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

CaliPharms Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About KGET

What is the current price of CaliPharms?

What is the 52-week range for CaliPharms?

How much debt does CaliPharms have?

How much cash does CaliPharms have on hand?

What is CaliPharms’s dividend yield?

Premium Investing Services